An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Infection and Immunity

• Publication date

  1992-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/iai.60.2.485-490.1992PMID 1730480PMCID PMC257653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin

  1991cited by this paper
• Reproduction of Edema Disease of Swine with Purified Shiga-like Toxin-II Variant

  1991cited by this paper
• Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes

  1990cited by this paper
• Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants

  1990influential reference
• Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits

  1990influential reference
• Infection by verocytotoxin-producing Escherichia coli

  1989cited by this paper
• Role of glutamic acid 177 of the ricin toxin A chain in enzymatic inactivation of ribosomes

  1989cited by this paper
• Selection and characterization of ricin toxin A-chain mutations in Saccharomyces cerevisiae

  1989cited by this paper
• Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

  1988cited by this paper
• Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I.

  1988influential reference
• Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

  1988cited by this paper
• Escherichia coli strains isolated from pigs with edema disease produce a variant of Shiga-like toxin II

  1987cited by this paper
• Production of Shiga-like toxin by Escherichia coli.

  1986cited by this paper
• Colonic biopsy in verotoxin-induced hemorrhagic colitis and thrombotic thrombocytopenic purpura (TTP).

  1986cited by this paper
• The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

  1985cited by this paper
• Epidemic Shiga bacillus dysentery in Central Africa.

  1984cited by this paper
• Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli

  1983cited by this paper
• Quantitative microtiter cytotoxicity assay for Shigella toxin

  1980cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Experimental edema disease of swine (E. coli enterotoxemia). 3. Pathology and pathogenesis.

  1974cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969.

  1970cited by this paper
• of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Shiga and Shiga-Like Toxins Shiga and Shiga-Like Toxins

  year unknowncited by this paper
• Site of Action of a Vero Toxin ( VT 2 ) from Escherichia coli O 157 : H 7 and of Shiga Toxin on Eukaryotic Ribosomes

  year unknowncited by this paper

• B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded α-helical coiled coil protects piglets from porcine edema disease.

  2025cites this paper
• Recombinant rSF toxoid enhances efficacy of bacterin-inactivated vaccine against F18+ Escherichia coli-induced edema disease in swine

  2025cites this paper
• Simultaneous Use of Iron/Anticoccidial Treatment and Vaccination against Oedema Disease: Impact on the Development of Serum-Neutralising Antibodies, Hematinic and Anticoccidial Activities in Piglets

  2024cites this paper
• Prevalence of antibody and toxin against edema disease from pig farms in Jeonbuk province

  2023cites this paper
• Induction of antitoxic antibody and preventive effect against porcine edema disease by the pentameric Stx2eB subunit vaccine

  2023cites this paper
• Oral Immunization with Attenuated Salmonella Choleraesuis Expressing the FedF Antigens Protects Mice against the Shiga-Toxin-Producing Escherichia coli Challenge

  2023cites this paper
• Evaluation of the prophylactic potential of non-enterotoxigenic Escherichia coli (non-ETEC) vaccine immunization and dietary mannan oligosaccharide competitive exclusion benefits against ETEC infections in weaned pigs

  2022cites this paper
• Immunogenicity of a live bivalent non-enterotoxigenic Escherichia coli (non-ETEC) vaccine and dietary clinoptilolite efficacy against postweaning diarrheal disease of pigs due to F4+ and F18+ ETEC strains

  2022cites this paper
• Immunity to bacterial pathogens of pigs and chickens

  2021cites this paper
• Shiga toxin suppresses noncanonical inflammasome responses to cytosolic LPS

  2020cites this paper
• Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli

  2020cites this paper
• Structural and Functional Characterization of Stx2k, a New Subtype of Shiga Toxin 2

  2019cites this paper
• Comparison of protective efficacy of Stx2eA toxoid with Salmonella ghosts carrying F18+STEC antigenic proteins against lethal challenge in the murine model

  2019cites this paper
• A Multicenter, Randomized Field Trial on the Efficacy and Safety of VEPURED ® , A New Vaccine Against Edema Disease in Pigs

  2019cites this paper
• Reduced mortality and morbidity associated with verotoxin 2e-induced edema disease in pigs using a recombinant verotoxin 2e vaccine

  2018cites this paper
• 12-1-2006 Bovine immune response to shiga-toxigenic Escherichia coli O 157 : H 7

  2018cites this paper
• Conclusions and a Glimpse into the Future

  2017cites this paper
• Effectiveness of F18+ Fimbrial Antigens Released by a Novel Autolyzed Salmonella Expression System as a Vaccine Candidate against Lethal F18+ STEC Infection

  2016cites this paper
• Validation of Two New Immunoassays for Sensitive Detection of a Broad Range of Shiga Toxins

  2016cites this paper
• Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle

  2015cites this paper
• Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

  2013cites this paper
• Evaluation of Recombinant Forms of the Shiga Toxin Variant Stx2eB Subunit and Non-Toxic Mutant Stx2e as Vaccine Candidates against Porcine Edema Disease

  2013cites this paper
• Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk.

  2013influential citation
• Large‐scale preparation of Shiga toxin 2 in Escherichia coli for toxoid vaccine antigen production

  2013cites this paper
• Effectiveness of Egg Yolk Antibody Against Shiga Toxin II Variant Toxicity In Vitro and In Vivo

  2013cites this paper
• Simple Method for Shiga Toxin 2e Purification by Affinity Chromatography via Binding to the Divinyl Sulfone Group

  2013cites this paper
• Protection of Piglets against Edema Disease by Maternal Immunization with Stx2e Toxoid

  2011cites this paper
• Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection.

  2011cites this paper
• Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.

  2010cites this paper
• Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins.

  2009cites this paper
• Role of shiga toxin dissemination and inflammation in the pathogenesis of shiga toxin-producing Escherichia coli infection

  2009cites this paper
• Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection.

  2009cites this paper
• A DNA Vaccine Encoding the Enterohemorragic Escherichia coli Shiga-Like Toxin 2 A2 and B Subunits Confers Protective Immunity to Shiga Toxin Challenge in the Murine Model

  2009cites this paper
• Histomorphometric characteristics of immune cells in small intestine of pigs perorally immunized with vaccine candidate F18ac+ nonenterotoxigenic E. coli strain

  2009cites this paper
• Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production.

  2008cites this paper
• Desenvolvimento de uma nova estratégia vacinal contra Síndrome Hemolítica Urêmica utilizando linhagens geneticamente modificadas de Bacillus subtilis capazes de expressar a toxina Stx2 de EHEC

  2007cites this paper
• Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge.

  2006cites this paper
• Bovine Immune Response to Shiga-Toxigenic Escherichia coli O157:H7

  2006cites this paper
• Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.

  2006cites this paper
• Protective Immunization of Mice with an Active-Site Mutant of Subtilase Cytotoxin of Shiga Toxin-Producing Escherichia coli

  2005cites this paper
• Shigatoxemia Conjugate Vaccine Protects Mice from B-Subunit-Keyhole Limpet Hemocyanin Recombinant Shiga Toxin

  2005cites this paper
• Recombinant Shiga Toxin B-Subunit-Keyhole Limpet Hemocyanin Conjugate Vaccine Protects Mice from Shigatoxemia

  2005cites this paper
• Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli

  2004cites this paper
• Protection against Shiga Toxin 1 Challenge by Immunization of Mice with Purified Mutant Shiga Toxin 1

  2003cites this paper
• Vaccination of weaned pigs against oedema disease.

  2003cites this paper
• Development of DNA Vaccines against Hemolytic-Uremic Syndrome in a Murine Model

  2003cites this paper
• Binding of Shiga Toxin 2e to Porcine Erythrocytes In Vivo and In Vitro

  2003cites this paper
• Persistence of Escherichia coli O157:H7 in experimentally infected swine.

  2002cites this paper
• Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.

  2002cites this paper
• Protection of Monkeys against Shiga Toxin Induced by Shiga Toxin-Liposome Conjugates

  2002cites this paper
• Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli.

  2001cites this paper
• A Rapid Bioluminescent Enzyme Immunoassay (BLEIA) for the Detection of Shiga Toxin Types 1 and 2

  2001cites this paper
• Genetically modified Shiga toxin 2e (Stx2e) producing Escherichia coli is a vaccine candidate for porcine edema disease.

  2001cites this paper
• Edema disease.

  2000cites this paper
• Shiga toxin-producing Escherichia coli infection: temporal and quantitative relationships among colonization, toxin production, and systemic disease.

  2000cites this paper
• Persistent Colonization of Sheep byEscherichia coli O157:H7 and Other E. coliPathotypes

  2000cites this paper
• Shiga Toxin-Induced Tumor Necrosis Factor Alpha Expression: Requirement for Toxin Enzymatic Activity and Monocyte Protein Kinase C and Protein Tyrosine Kinases

  2000cites this paper
• Shiga Toxins of Shigella dysenteriae and Escherichia coli

  2000cites this paper
• Mechanisms in the Pathogenesis of Enteric Diseases 2

  1999cites this paper
• Edema disease as a model for systemic disease induced by Shiga toxin-producing E. coli.

  1999cites this paper
• Pathogenesis and Diagnosis of Shiga Toxin-Producing Escherichia coli Infections

  1998cites this paper
• Prevention of edema disease in pigs by vaccination with verotoxin 2e toxoid.

  1997cites this paper
• Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains

  1997cites this paper
• Transformation of a non-enzymatic toxin into a toxoid by genetic engineering.

  1997cites this paper
• 病原性大腸菌O157(腸管出血性大腸菌)の産生するVero毒素の性状

  1996cites this paper
• Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR

  1996cites this paper
• Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine

  1996influential citation
• Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs.

  1995cites this paper
• [The immune response in edema disease of weaned piglets measured with a recombinant B subunit of shiga-like toxin II].

  1995cites this paper
• Construction of Mutant Genes for a Non‐Toxic Verotoxin 2 Variant (VT2vp1) of Escherichia coli and Characterization of Purified Mutant Toxins

  1994cites this paper
• Bacterial immunogens and protective immunity in swine.

  1994cites this paper
• Characterization of non-toxic mutant toxins of Vero toxin 1 that were constructed by replacing amino acids in the A subunit.

  1993cites this paper
• Summary of the 27th United States-Japan Joint Conference on Cholera and Related Diarrheal Diseases.

  1993cites this paper
• Vero Toxins (Shiga‐Like Toxins) Produced by Enterohemorrhagic Escherichia coli (Verocytotoxin‐Producing E. coli)

  1993cites this paper
• Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice

  1993cites this paper